Abstract
Cancer cells display an overproduction of reactive oxygen species resulting from an exaggerated intrinsic oxidative stress. However, the concept of deleterious oxidants versus beneficial antioxidants has recently evolved. Indeed, molecules like natural coumarins have shown anti-oxidant or pro-oxidant properties depending on their intracellular concentration. Therefore, we have investigated the structure-activity relationship of a variety of coumarin derivatives in terms of cytotoxicity towards human and murine carcinoma cell lines (HT29, HepG2, A549, MCF7, OVCAR and CT26). Amongst those compounds, (E)-7-methoxy-4-(3-oxo-3- phenylprop-1-enyl)-2H-chromen-2-one and (E)-7-hydroxy-4-(3-(4-hydroxyphenyl)-3-oxoprop-1-enyl)-2H-chromen-2-one displayed the most potent cytotoxic effect on colon cancer cells, CT26, (IC50=4.9µM) linked to their pro-oxidant properties. Those compounds triggered the in vitro production of reactive oxygen species by tumor cells, leading to their death through a necrotic process. In vivo, molecules also slowed down tumor growth by 65.7% and 35.4%, respectively, without inducing significant side effects.
Keywords: Cancer, coumarin, cytotoxicity, oxidative stress, structure-activity relationship.
Anti-Cancer Agents in Medicinal Chemistry
Title:Chalcone-Coumarin Derivatives as Potential Anti-Cancer Drugs: An in vitro and in vivo Investigation
Volume: 14 Issue: 7
Author(s): Vincent Jamier, Wioleta Marut, Sergio Valente, Christiane Chereau, Sandrine Chouzenoux, Carole Nicco, Herve Lemarechal, Bernard Weill, Gilbert Kirsch, Claus Jacob and Frederic Batteux
Affiliation:
Keywords: Cancer, coumarin, cytotoxicity, oxidative stress, structure-activity relationship.
Abstract: Cancer cells display an overproduction of reactive oxygen species resulting from an exaggerated intrinsic oxidative stress. However, the concept of deleterious oxidants versus beneficial antioxidants has recently evolved. Indeed, molecules like natural coumarins have shown anti-oxidant or pro-oxidant properties depending on their intracellular concentration. Therefore, we have investigated the structure-activity relationship of a variety of coumarin derivatives in terms of cytotoxicity towards human and murine carcinoma cell lines (HT29, HepG2, A549, MCF7, OVCAR and CT26). Amongst those compounds, (E)-7-methoxy-4-(3-oxo-3- phenylprop-1-enyl)-2H-chromen-2-one and (E)-7-hydroxy-4-(3-(4-hydroxyphenyl)-3-oxoprop-1-enyl)-2H-chromen-2-one displayed the most potent cytotoxic effect on colon cancer cells, CT26, (IC50=4.9µM) linked to their pro-oxidant properties. Those compounds triggered the in vitro production of reactive oxygen species by tumor cells, leading to their death through a necrotic process. In vivo, molecules also slowed down tumor growth by 65.7% and 35.4%, respectively, without inducing significant side effects.
Export Options
About this article
Cite this article as:
Jamier Vincent, Marut Wioleta, Valente Sergio, Chereau Christiane, Chouzenoux Sandrine, Nicco Carole, Lemarechal Herve, Weill Bernard, Kirsch Gilbert, Jacob Claus and Batteux Frederic, Chalcone-Coumarin Derivatives as Potential Anti-Cancer Drugs: An in vitro and in vivo Investigation, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (7) . https://dx.doi.org/10.2174/1871520613666131224124445
DOI https://dx.doi.org/10.2174/1871520613666131224124445 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Current Drug Discovery Technologies Advances in Stem Cell Therapy for Leukemia
Current Stem Cell Research & Therapy Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Current Understanding of Dietary Polyphenols and their Role in Health and Disease
Current Nutrition & Food Science Novel and Emerging Drugs for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities
Current Topics in Medicinal Chemistry Intraperitoneal Chemotherapy as First-Line Treatment in the Management of Epithelial Ovarian Cancer
Mini-Reviews in Medicinal Chemistry Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design New Insights on the Mode of Action of Microcystins in Animal Cells - A Review
Mini-Reviews in Medicinal Chemistry Targeting the mTOR Pathway in Tumor Malignancy
Current Cancer Drug Targets Bioplex Technology: Novel Synthetic Gene Delivery Pharmaceutical Based on Peptides Anchored to Nucleic Acids
Current Pharmaceutical Design MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Animal Models for Growth Hormone Gene Therapy
Current Gene Therapy Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy
Current Pharmaceutical Design Role of Chitosan Biomaterials in Drug Delivery Systems: A Patent Perspective
Recent Patents on Materials Science The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued)